Here is the design of a clinical trial:

Official Title: Impact of a Pediatric-adult Care Transition Program on the Health Status of Patients With Sickle Cell Disease - A Randomized Controlled Trial

Included conditions:
- Sickle Cell Disease

Study Armgroups:
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Patients included in this arm wil have usual follow-up.'}
- {'label': 'Care transitional program', 'type': 'EXPERIMENTAL', 'description': 'Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent\n\nThree axes are :\n\n* Educative, family (patient and parent), at home\n* Psychological, with the patient individually\n* Medico-social orientation, group of patients', 'interventionNames': ['Other: pediatric-adult care transition program']}

Interventions:
- {'type': 'OTHER', 'name': 'pediatric-adult care transition program', 'description': 'Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent\n\nThree axes are :\n\n* Educative, family (patient and parent), at home\n* Psychological, with the patient individually\n* Medico-social orientation, group of patients', 'armGroupLabels': ['Care transitional program']}

Primary Outcomes:
- {'measure': 'Incidence of sickle cell related severe complications leading to hospitalization', 'description': 'Number of hospital admission or emergency visit in the index hospital', 'timeFrame': 'Within 24 months after transfer to the adult sector'}

Please estimate the sample size based on the assumption: 
80% power, two-sided test at a significance level of 5%, and a 10% inflation factor to account for study deviations such as missing data, withdrawal, and loss to follow-up.
Sample size and recruitment
        A total of 196 (98 in each group) is required to detect at least a 15% reduction of the hospitalisation rate for complications 2 years after the transfer in the intervention group compared to the control group. This reduction assumes a hospitalisation rate of 3.5 per patient per year [7] with 80% power and the use of a two-sided test at a significance level of 5% and a 10% inflation factor to anticipate study deviations (missing data, withdrawal, loss to follow-up).
        Participants are recruited in the hospital when they come for a medical consultation or at the end of a hospitalisation for complications. Potential participants are screened. The investigator informs the patient and caregiver about the study, following which the patient gives oral consent and the patientâs caregiver the written informed consent for patient participation. The information note and consent form is presented in Additional file 1. When the patient legally becomes an adult (i.e. at 18âyears of age in France), he will give his/her own written informed consent.